LLY250117P905000
- 0.00
- 0.000.00%
Eli Lilly and Co Newsroom
On the first day of the JPM Medical Conference, pharmaceutical giants are announcing new strategies. Could the mergers and acquisitions in Biomedical begin in 2025?
In 2025, the Biomedical mergers and acquisitions will begin.
Eli Lilly and Co (LLY.US) CEO: The oral weight loss drug is expected to be approved as early as the beginning of next year.
Eli Lilly and Co's CEO David Ricks stated on Monday that the company expects its experimental oral weight loss drug to be approved as early as the beginning of next year.
The arrangement for Trump's inauguration ceremony has been announced: it is expected to cost 0.037 million dollars per minute.
① The inauguration activities of the president-elect Trump in the USA have been announced, including an official party, a MAGA rally, and a large fireworks display, with multiple events taking place at Trump's golf course outside Washington, D.C. ② Trump's inaugural committee has raised over $0.17 billion, expected to reach $0.2 billion, spending $0.037 million per minute, far exceeding the record of $8,600 per minute set during Obama's first inauguration.
Eli Lilly and Co plans to acquire cancer drug developer Scorpion Therapeutics for 2.5 billion dollars.
GlobeNewswire on January 14 | Eli Lilly and Co announced on Monday that it plans to acquire the experimental cancer therapy from Scorpion Therapeutics for up to 2.5 billion dollars in cash, in order to expand its cancer treatment product line. The company will acquire Scorpion's experimental oral therapy STX-478, which is currently undergoing early trials for breast cancer and other advanced solid tumors.
Obesity Drug Developer Metsera Files for $100M IPO
Sector Update: Health Care Stocks Gain Monday Afternoon
Market Chatter: Eli Lilly Expects Approval of Experimental Weight-Loss Pill by Early 2026
Lilly Asked Feds to Pause Drug Pricing Negotiations: Report
Eli Lilly and Co (LLY.US) expects that the new weight loss drug will be approved early next year.
Eli Lilly and Co's CEO Dave Ricks stated that the experimental weight loss drug orforglipron is expected to receive approval as early as early 2026. Ricks mentioned that the pill would be more convenient for patients and easier to mass produce. Eli Lilly and Co's injectable weight loss medication is in short supply, partly due to production limitations.
Express News | Eli Lilly and Co requests the Biden administration to pause the negotiation on pharmaceutical prices.
Express News | Lilly Asks Biden Administration to Pause Drug-Price Negotiations- Bloomberg News
The anti-obesity drug battle escalates! The CEO of Eli Lilly and Co reveals that the company's oral medication may be released early next year.
① Eli Lilly and Co's CEO David Ricks expects that its experimental oral weight-loss drug orforglipron will be approved as early as early 2026; ② The phase II trial data for orforglipron shows significant weight loss in participants, with clinical significance; ③ Although Eli Lilly and Co is once again trailing Novo-Nordisk A/S, its weight-loss injectable has completely surpassed semaglutide in head-to-head studies.
Johnson & Johnson Makes $15 Billion Bet on Mental-health Drugs
The Top and Bottom Contributors to S&P 500's Q4 EPS Growth
Lilly Oral Obesity Drug Could Get FDA Okay in Early 2026: Report
Express News | Eli Lilly and Co expects that its experimental weight-loss drug will be approved as early as early 2026.
Express News | Eli Lilly Is Projecting Approval of Its Experimental Weight-Loss Pill as Soon as Early 2026 - Bloomberg News
Eli Lilly and Co (LLY.US) has spent 2.5 billion dollars to acquire cancer drug developer Scorpion Therapeutics.
Eli Lilly and Co (LLY.US) announced on Monday plans to acquire Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash, in order to expand its cancer treatment portfolio. The company will acquire Scorpion's experimental oral therapy STX-478, which is currently undergoing early trials for breast cancer and other advanced solid tumors.
Express News | Eli Lilly and Co will acquire Scorpion's cancer drugs for up to $2.5 billion.
Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5B Deal